Treatments for the annual 1.8M new cancer patients rely on radiation/chemotherapy/surgery. For the annual 600k patients that exhaust these standard clinical options, DNA precision medicine is the most commonly offered next option. However, DNA-based approaches fail to help >70% of cancer patients, leaving a huge patient population with fatal unmet clinical needs. Nonetheless, within the $90B cancer treatment industry, precision medicine for cancer now represents a $1Band growing market (200k precision medicine tests per year), most of which is not working.
First Ascent will revolutionize the way cancer is treated by using cutting-edge molecular biology (functional drug testing and DNA/RNA sequencing), bioinformatics, and AI technologies to tailor personalized drug combinations to each patient’s cancer. Our published (10+ publications) and validated AI approach builds a “circuit” blueprint of each cancer to understand WHY drugs are effective.
We believe this is the future of canc...
Treatments for the annual 1.8M new cancer patients rely on radiation/chemotherapy/surgery. For the annual 600k patients that exhaust these standard clinical options, DNA precision medicine is the most commonly offered next option. However, DNA-based approaches fail to help >70% of cancer patients, leaving a huge patient population with fatal unmet clinical needs. Nonetheless, within the $90B cancer treatment industry, precision medicine for cancer now represents a $1Band growing market (200k precision medicine tests per year), most of which is not working.
First Ascent will revolutionize the way cancer is treated by using cutting-edge molecular biology (functional drug testing and DNA/RNA sequencing), bioinformatics, and AI technologies to tailor personalized drug combinations to each patient’s cancer. Our published (10+ publications) and validated AI approach builds a “circuit” blueprint of each cancer to understand WHY drugs are effective.
We believe this is the future of cancer treatment, and we have interrogated this belief through two independent customer discovery processes: we have validated the need for personalized cancer technology with clinicians (NSF I-CORPS) and patients (MBA capstone project interviewing 120+ customers). As cancer technologies advance, the First Ascent platform will be the starting point to personalize each patient’s treatment, whether personalized drug combinations or other approaches. We will provide patients access to the deep biological knowledge afforded by n-of-one studies and the insight provided by artificial intelligence, while easing the burdens of oncologists who want to provide their patients with personalized approaches but lack the necessary time and resources.
More information

Employees

Noah Berlow
Admin
Noah Berlow CTO Electrical Engineer/Bioinformatics/Molecular Biologist/Cancer Researcher